News

His presentation at South Beach Symposium will feature Zirwas’ insights on JAK inhibitors, eczema treatments, and emerging therapies.

Goldberg noted combination treatments that integrate radiofrequency, ultrasound, and muscle stimulation could improve patient outcomes.

Catch up on coverage from the first day of the 2025 South Beach Symposium held in Miami Beach, Florida.

“The most important tip as a physician, when you talk to the patient, sit down. Even if you sit down for 5 minutes, it's worth almost 5 hours,’ Leon Kircik, MD, said in his interview with Dermatology Times at SBS 2025.

Nada Elbuluk, MD, MSc, emphasizes that medical treatments remain first-line for vitiligo, but stable cases may benefit from surgical options.

Ablon covered all aspects of getting involved in clinical research, such as budgeting, recruiting, and analyzing data.

Michael Gold, MD, shares why the South Beach Symposium remains a must-attend legacy event for dermatologists, blending education and innovation.

According to Silverberg, emotional resilience, social support, and purposeful activities help adolescents cope with acne-related stress.

Nanette Silverberg, MD, highlights new dermatology advancements and the significance of conferences like MOPD in shaping the future of treatment.

Study author Erin McClure, MD, discusses how IGSRT offers consistent NMSC recurrence rates across socioeconomic and comorbidity factors, reinforcing its role as a first-line treatment.

The initiative, created by Quoin, promotes educational resources and study updates about the rare disease.

Dermatology Times staff will be onsite covering SBS 2025 with expert insights, interviews, and breaking news.

In an interview ahead of the main event, Ablon shared her excitement for SBS and listening in on presentations from industry leaders.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a woman aged 35 years with widespread eczematous lesions covering over 50% BSA and severe lichenification.

New data reveals an unmet need in the management of moderate to severe psoriasis in Greek patients.

The new dose offers a more tailored and convenient option for patients with inflammatory conditions.

New RELAX trial data show Relfydess delivers rapid onset and 6-month efficacy.

We want to know: Will you be attending the symposium in Miami Beach this week?

Maximize your AAD 2025 experience with expert tips on education, networking, and navigating the exhibit hall in Orlando.

This review of the latest dermatologic studies includes insights into the efficacy of nutraceuticals in noncystic acne, the role of antimicrobial peptides in the skin barrier, and more.

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

High concentrations of particulate matter can potentially lessen the exposure to UV radiation.

Start the new year with a look at top dermatology conferences, expert insights, and the latest research on pigmentary disorders, psoriasis, and antiaging treatments.

Patients saw improvement in hydration, sebum, erythema, and scarring after just 3 treatment sessions.

In his presentation at Winter Clinical Miami, Del Rosso covered a variety of topics including refractory pediatric vitiligo.

Biologic coordinators play a key role in managing insurance approvals and ensuring coverage details are confirmed quickly, often within 48 hours.

The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.

Answer today’s poll and read more about the validity of dermatological content being shared on TikTok.

The clinically-backed, post-procedure sunscreen is designed to enhance skin healing, reduce redness, promote hydration, and provide broad-spectrum UV protection.